Vibhu Jain
4 Nov • 7:31 AM · SEBI-Registered Analyst
Orchid Pharma analysis on different parameters
ORCHPHARMA Quality :- The company’s quality metrics are assessed as average, reflecting a stable but unremarkable operational profile. Over the last five years, operating profit has grown at an annual rate of approximately 15.60%, indicating moderate expansion in core earnings. However, this growth has not translated into strong profitability ratios, with the average return on equity (ROE) hovering near 4.82%, a figure that suggests limited efficiency in generating shareholder returns. Valuation :- Valuation metrics suggest that the stock is trading at a premium relative to its peers and historical averages. The enterprise value to capital employed ratio is approximately 3.4, which is considered very expensive in the context of the company’s subdued profitability and flat financial results. This premium valuation may reflect investor expectations of future growth or sector-specific optimism, but it also introduces a degree of risk should earnings fail to meet these expectations. Financial :- Financial trends reveal some concerns, particularly regarding the company’s leverage and capital structure. The debt to EBITDA ratio is notably high at 14.73 times, signalling a significant debt burden relative to earnings before interest, tax, depreciation, and amortisation. This elevated leverage raises questions about the company’s ability to service its debt obligations comfortably over the long term. Technical :- technical standpoint, the stock exhibits mildly bullish characteristics. Recent price movements include a one-day gain of 1.37% and a one-week increase of 2.70%, although the one-month and three-month returns have been negative, at -13.51% and -13.14% respectively. Over six months, the stock has rebounded with a 36.45% gain, underscoring some volatility but also resilience in the medium term.
See More


